Aarti Drugs Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xlf3vo765376cemzdmlcjqk5.pdf

Key Takeaways


Revenue & Pricing Dynamics

Adhish Patil: "Typically, the purchasing people at the formulation side, they try to refrain overstocking the product because the prices have suddenly gone up due to geopolitical reasons. So, there is a waiting game here. So, once they start believing that this is a new normal, then the volume growth and the demand should start to come in."

Formulations: The Breakout Quarter

Vishwa Savla: "So, while this was an exceptional quarter, but we believe that now with our entry into newer markets and newer products, we will be able to sustain a similar level of revenue."

Margin Structure & Sustainability

Adhish Patil: "These gains in product mix, backward integration and cost efficiency are structural and they will stay with us even as the pricing environment normalizes over time."

Capacity Expansion & Capex Pipeline

ProjectDetailsTimeline
Tarapur USFDA block expansionAdjacent block with three new multipurpose plants for regulated markets, more than doubling capacityCommercial production targeted end of FY29 (18 to 20 months)
Sarigam metformin capacityIncrease from 1,400 to 1,700 tonnes/monthCommercialization early FY28
Sarigam USFDA metformin blockDedicated 500 tonnes/month block; USFDA DMFs under preparation; expected to open US and EU marketsEnd of FY28
Baddi brownfield expansionAdjacent plot to nearly double oral solid dosage manufacturing capacityMid-next year
Tarapur methyl salicylateTechnical grade production started; roughly 85 tonnes manufactured in Q2 FY27Already operational

Strategic Direction & Regulatory Catalysts

Adhish Patil: "So, going forward, we are actually working on a business plan for the next, you can say five to seven years, which includes introducing a mixed bucket of molecules. Some of them would be similar to what we do, where our strength lies. Some of them would be a bit more niche molecules in APIs. And we are also trying to develop competencies on a CDMO platform."

Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated EBITDA margin15% sustainableOngoing
Formulation revenueCurrent level sustainable for rest of yearFY27
Formulation marginSteady-state 20% (versus 28% in Q2)Beyond current 4-month order book
Volume growthHigh single-digit possible if buyers accept new pricing normalConditional on buyer behavior
Tarapur USFDA blockCommercial productionEnd of FY29
Sarigam metformin expansion1,700 tonnes/monthEarly FY28
Sarigam USFDA metformin block500 tonnes/month dedicated blockEnd of FY28
Baddi formulation expansionDouble oral solid dosage capacityMid-next year
US oncology revenue rampIncrease from small Q2 contribution3 to 6 months
Oncology ANDA pipelineOne more approval in next few months; 4 to 5 filings in rolling 12 monthsNext 12 months
Anti-dumping duty processDGTR initiation before December year-end; completion in 3 to 6 months thereafterInitiation by Dec 2025; completion mid-2026
Complex API/CDMO capex planClearer picture on capex and capital assignment4 to 5 months
Oncology revenue targetLate 30s to early 40s percent of revenueFY30

Key Metrics

MetricQ2 FY27
Consolidated revenue₹829 cr, +27% YoY
Consolidated EBITDA₹138 cr, +63% YoY
Consolidated EBITDA margin16.6%, +370 bps YoY, highest in nearly 6 years
Consolidated PAT₹83 cr, +83% YoY
Consolidated PAT margin10.0%, +310 bps YoY
Standalone revenue₹709 cr, +22% YoY
Standalone domestic revenue growth+43% YoY
Standalone export revenue growth-5% YoY
API segment revenue₹605 cr, +17% YoY
Specialty chemicals revenue₹72 cr, +92% YoY
Formulations revenue₹130 cr, +58% YoY; exports contributed 74%
Formulations EBITDA margin~28%, exceptional due to export orders
Standalone volume growth (API + spec chem)~5% YoY
Standalone realization growth~17–18% YoY
Methylamines facility utilization (Saykha)~72%
Captive consumption of antidiabetic portfolio~85%
Technical grade methyl salicylate produced (Tarapur)~85 tonnes in the quarter
Formulations pending export order book~4 months visibility
H1 FY27 operating cash flow~₹90 cr, standalone and formulation roughly equal